Ivor Royston

Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team

Retrieved on: 
Tuesday, July 6, 2021
Epstein–Barr virus, Infectious causes of cancer, Esperion Therapeutics, EBV, Ivor Royston, Lymphoma, Medical specialties, Health, Clinical medicine, Viral structural proteins

SAN DIEGO, July 6, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc.(Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer.

Key Points: 
  • SAN DIEGO, July 6, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc.(Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer.
  • "Ayman is one of the world's leading experts on Epstein-Barr virus (EBV)-associated cancers and a tremendous addition to our management team," said Ivor Royston, M.D., President and Chief Executive Officer of Viracta.
  • Our impressive clinical data has validated the approach, and I am thrilled to have the opportunity to join Viracta as Chief Scientific Officer at this very exciting time.
  • Patric Nelson, MBA,joined Viracta from Esperion Therapeutics, where he served as Vice President, Business Development and Alliance Management.

Viracta Announces Appointment of Lisa Rojkjaer, MD, as Chief Medical Officer

Retrieved on: 
Wednesday, March 25, 2020
Infectious causes of cancer, RTT, Causes of death, Nasopharynx cancer, Pharynx, Ivor Royston, Cancer, Epidemiology, Health, Epstein–Barr virus

SAN DIEGO, March 25, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Lisa Rojkjaer, MD, as Chief Medical Officer (CMO), effective May 1, 2020.Dr.

Key Points: 
  • SAN DIEGO, March 25, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Lisa Rojkjaer, MD, as Chief Medical Officer (CMO), effective May 1, 2020.Dr.
  • "Viracta has grown substantially over the past year and our pipeline has many compelling opportunities to treat virus-associated cancers," said Ivor Royston, MD, President and Chief Executive Officer of Viracta.
  • Prior to joining Viracta, Dr. Rojkjaer served as Chief Medical Officer of Nordic Nanovector, a publicly traded precision oncology company located in Oslo, Norway, where she led the clinical development and medical affairs functions.
  • Viracta is pursuing application of this Kick and Kill platform approach in other EBV associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma and other viral related cancers.

Viracta's Precision Oncology Research in EBV+ Cancers Highlighted at 16th Annual UCSD Moores Cancer Center Symposium

Retrieved on: 
Tuesday, February 18, 2020
Cancer, Infectious causes of cancer, Causes of death, Nasopharynx cancer, Pharynx, Histone deacetylase, Ivor Royston, Epstein–Barr virus

It is estimated that there are over 200,000 new cases of EBV-associated cancers each year.

Key Points: 
  • It is estimated that there are over 200,000 new cases of EBV-associated cancers each year.
  • "We are honored that Viracta's research and clinical findings have been recognized among the world-renowned leaders at the UCSD Moores Cancer Center," said Ivor Royston, M.D., President and CEO of Viracta.
  • UCSD Moores Cancer Center presentation details are as follows:
    Location: Moores Cancer Center at UCSD Health, San Diego, CA
    Nanatinostat (VRx-3996) is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta.
  • Viracta is pursuing application of this Kick and Kill treatment approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other viral-related cancers.

Viracta Therapeutics to Present at the 5th Annual Solebury Trout Private Company Showcase

Retrieved on: 
Monday, October 14, 2019
Infectious causes of cancer, RTT, Nasopharynx cancer, Pharynx, Wardwell, Ivor Royston, Cancer, Health, Epstein–Barr virus, Clinical medicine, Medicine

SAN DIEGO, Oct. 14, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced today that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a company overview at the 5th Annual Solebury Trout Private Company Showcase in New York, NY on Friday, October 18, 2019 at 11:00 am ET at the offices of Davis Polk & Wardwell, LLP (Davis Polk).

Key Points: 
  • SAN DIEGO, Oct. 14, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced today that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a company overview at the 5th Annual Solebury Trout Private Company Showcase in New York, NY on Friday, October 18, 2019 at 11:00 am ET at the offices of Davis Polk & Wardwell, LLP (Davis Polk).
  • The Private Company Showcase is hosted together by David Polk, BMO, Donnelly Financial Solutions (DFIN) and CFGI.
  • Viracta is a precision oncology company targeting virus-associated malignancies.
  • Viracta is pursuing application of this Kick and Kill approach in other EBV associated malignancies, such as nasopharyngeal carcinoma, and other virus-related cancers.

Viracta Strengthens Executive Management Team with New Appointments

Retrieved on: 
Thursday, August 1, 2019
Ivor Royston, CMC, Investigational New Drug, Health, Companies

Mr. Chevallard brings important financial and operational experience to Viracta and will lead the Company's finance functions.

Key Points: 
  • Mr. Chevallard brings important financial and operational experience to Viracta and will lead the Company's finance functions.
  • Dr. Deng brings significant product development and chemical manufacturing and controls (CMC) experience to Viracta and will oversee its investigational drug product development activities.
  • "We are thrilled to welcome Dan and Xiaohu to the Viracta team," said Ivor Royston, MD, Viracta's CEO.
  • Dr. Deng joins Viracta from Kura Oncology, Inc. and Wellspring Biosciences, where he was Senior Director, Head of CMC.